Next Article in Journal
Dynamic Changes in Microvascular Density Can Predict Viable and Non-Viable Areas in High-Risk Neuroblastoma
Previous Article in Journal
Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

The Pleiotropic Effects of Gut Microbiota in Colorectal Cancer Progression: How to Turn Foes into Friends

SSD Oncologia Molecolare e Angiogenesi, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(3), 916; https://doi.org/10.3390/cancers15030916
Submission received: 16 January 2023 / Accepted: 31 January 2023 / Published: 1 February 2023
(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)

1. Introduction

Colorectal Cancer (CRC) is one of most frequent malignant cancers, showing high lethality worldwide [1]. In the past, CRC was more frequently diagnosed in Western countries, but the recent economic development of other areas and spread of occidental habits are increasing CRC incidence in developing countries too [2,3]. These data indicate that environmental elements and lifestyle habits are important in triggering CRC carcinogenesis [4,5]. Red processed meat, saturated fats, and alcohol consumption, along with smoking, obesity, and physical inactivity, are linked to an increased CRC susceptibility [4]. Indeed, many CRC determinants could act as risk factors contributing, with different penetrance, to the overall cancerogenic effect. Nevertheless, CRC carcinogenesis is a very slow process that can manifest over 10 years, depending on the prevalence of genetic and epigenetic alterations.
Food does not act only directly on gut wellness [6,7]. Indeed, many studies described the importance of dietary habits in the modulation of gut microbiota (GM) composition, which in turn can act as a cofactor in CRC development [8,9]. The GM can be considered as a metabolic organ with a symbiotic affinity to the gut. Many different bacterial species contribute to GM composition, exerting several roles in maintaining the intestinal homeostasis. Healthy commensal bacteria produce essential metabolites from the fermentation of dietary fibers, preserving the GM equilibrium and reducing the infestation of pathogenic strains [9]. Another fundamental activity exerted by GM is the activation of the host immune system [10,11].
Bad eating habits, alcohol consumption, and cigarette smoking may favor the development of dysbiosis by the increased proliferation of aggressive bacterial (such as Fusobacterium (F.) nucleatum and Porphyromonas), viral, and fungal species [12]. This would lead to an imbalance in the composition, metabolism, and function of GM, which may precede the onset of CRC and several other gut diseases [13,14]. While everyone’s genetics is important in determining the final equilibrium of a personal GM, once the composition of bacterial flora is established, it is stable over time. Nevertheless, it still shows a relative plasticity when adapting to gut-perturbing factors [15,16]. Only a prolonged diet with junk food could progressively reduce the variety of favorable bacterial species, affecting intestinal homeostasis and leading to dysbiosis and epithelial permeability [17]. In addition to a healthy diet, regular physical exercise [18,19] and meditation [20] can positively affect gut wellness, promoting GM biodiversity and an enrichment in healthy bacteria, actively protecting the intestinal barrier from pathogens.
Alcoholado LS et al. proposed a valuable overview on the role of the GM in the development of CRC, indicating some strategies to prevent tumor onset [21]. In particular, they focused on the importance of the GM composition as a tiebreaker in promoting or contrasting dysbiosis, epithelial inflammation, and CRC. This review indicates bacterial metabolites promoting dysbiosis and how antibiotics reduce the bacterial protective biofilm favoring tissue invasion by pathogenic strains. On the other hand, the authors indicate diet-derived molecules (i.e., fibers and polyunsaturated fatty acids) that, once fermented by bacteria, contribute to maintain a healthy GM biocenosis. Finally, probiotics and bioactive compounds such as quercetin, anthocyanin, tannins, and curcumin are analyzed. These diet components can help to prevent several gut pathologies, are able to actively contrast some phases of tumor life-history, and can decrease the side effects of chemotherapy [21].

2. Microbiota and CRC Risk

Anaerobic fermentation operated by the gut microbiota produces different metabolites. Among those derived from undigested dietary components, there are polyamines. It is now evident that a CRC-associated microbiome can be directly involved in the dysregulated metabolism of polyamines [22]. Even if polyamines are fundamental constituents for normal cell growth, the data from a metabolomic screening of CRC tissues [22] revealed that the development of bacteria biofilm lining the gut is dependent on host-enhanced polyamine metabolism. Since polyamines are necessary components for cell membrane synthesis, they could directly contribute to the proliferation of CRC cells [22].
Antibiotics are additional risk factors that could indirectly promote colon carcinogenesis, affecting gut microbiota homeostasis [23]. Their ability to suppress many bacterial strains is associated with the decrease in crypt height and heme-induced lipoperoxidation under an enriched red-meat diet [24]. According to nested case–control studies on humans, the pro-oncogenic activity of antibiotics could be linked to either an imbalance of bacterial populations (also favoring fungi outgrowth) or the sudden increment of bacteria after antibiotics withdrawal [25,26]. Importantly, a chronic perturbation of gut microbiota at the end of antibiotics treatment might influence the long-term dysregulation of host immune homeostasis, impacting the immune reaction against CRC [23]. Finally, antibiotic-induced dysbiosis might also decrease the therapeutic efficacy of orally administered anti-cancer drugs, limiting their uptake by enterocytes [27].

3. Prevention of CRC Carcinogenesis

Epidemiological and clinical studies have found that diet plays a critical role in the induction or prevention of CRC. Since dietary products impact the gut microbiome, their reciprocal influence on CRC is evident. A diet enriched with fibers favorably affects the metabolic activities of the GI tract [28]. Interestingly, dietary fibers also reduce the risk of CRC. This favorable effect is linked not only to the quantity of fibers but also to their density [29]. Although, in the human-based EPIC study, the source of fibers was not apparently relevant [30], some mouse models suggest that short-chain carbohydrates, such as inulin, could be more beneficial [31]. Moreover, a higher intake of dietary fibers could improve patient survival also after CRC diagnosis [32].
The most important effect of dietary fibers is the favorable modulation of microbiota composition. In particular, a high-fiber diet diminished the risk of developing F. nucleatum-positive CRC [33], with F. nucleatum being responsible for increased inflammation and impaired immune reaction, which are both implied in colon carcinogenesis [34]. High fiber diets also increase the presence of butyrate-producing bacteria, which are important to ferment soluble fibers to short chain fatty acids (SCFAs) that, in turn, play a critical role in cancer prevention [35]. Saccharolytic fermentation and butyrogenesis induced by fibers are accompanied by the suppression of secondary bile acid synthesis, which is linked to a reduction in CRC risk [36].
Additionally, the assimilation of polyunsaturated fatty acids (PUFAs), such as omega-3, with diet could be beneficial to reduce CRC risk [37]. Similar to a high fiber intake, supplementation with PUFAs can decrease the presence of pathogenic bacteria and increase the presence of butyrate-producing bacteria. Of note, PUFAs act against the development of CRC also regulating the differentiation and apoptosis of colonocytes [38]. Moreover, they can act on the immune system and modulate CRC-related gene expression, decreasing the risk of high microsatellite instability (MSI) and possibly improving the DNA repair systems [39]. Nevertheless, since PUFAs composition is different in cancer and normal tissue, the metabolism of PUFAs also plays a role in inflammation and in the development of CRC [40].
Probiotics are valuable diet supplements. A regular supplementation with well-defined, healthy bacterial strains can modulate the composition of GM, reducing the inflammation caused by dysbiosis and favoring the restoration of the equilibrium [41]. Many probiotics are able to decrease gut epithelial cell permeability, increase the activity of the host immune system, indirectly activating the phagocytosis of cancer cells and reducing the side effects of chemotherapy [42,43].
Among the classes of phytochemicals that are able to favor eubiosis, there are polyphenols. These aromatic compounds are found at high concentrations in coffee, tea, cocoa, wine, fruits, vegetables, and whole-grain cereals. They can act both directly on host cells and on resident GM, being able to modulate its composition inhibiting the proliferation of many bacterial and viral strains. In CRC, polyphenols could significantly modulate the DNA repair system, decrease metastatic spread, and inhibit tumor neo-angiogenesis [44]. Moreover, polyphenol assumption could increase the anti-cancer potential of some drugs [45,46,47].

4. Conclusions

The review of Alcoholado et al., starting from the overview of the mechanisms mediating the involvement of GM in the development of CRC, underlies how gut microbiota can be modulated to contrast it. As reported, a regular intake of positive modulators (fibers, PUFAs, and probiotics) can avoid dysbiosis and intestinal inflammation, thus contributing to CRC prevention. Importantly, the plasticity of the microbiome could also impact the host’s environmental fitness in the short or long term, improving or reducing the assimilation of nutrients or toxins [15]. In this perspective, species-specific GM could have co-evolved in parallel with their host.
As the influences of GM and the gut are reciprocal, behaviors able to modify gut motility or food adsorption can strongly perturb microbiome homeostasis. For example, physical activity might change the bacterial composition and counteract dysbiosis in CRC patients [18,19,48]. Moreover, there are some data about meditation-based therapy that, reducing stress, could indirectly act on the health of GM [20,49].
In support of numerous hypotheses, the EPIC perspective trial followed 519,978 healthy human subjects from 10 countries over years [30]. EPIC was able to show a clear, favorable relation between fiber consumption and reduced CRC onset. Large, perspective epidemiologic studies on the healthy human population such as EPIC are usually prohibitive in terms of costs and time, thus alternative approaches are needed. Using GM composition analysis as a surrogate marker of gut wellness, clinical and preclinical studies might be implemented to identify multidisciplinary (diet, exercise, and meditation) approaches able to prevent or delay CRC onset. In the meantime, the education of the general population towards healthier lifestyle habits appears to be the only immediate approach for limiting CRC incidence.

Author Contributions

Conceptualization, S.T.; writing—original draft preparation, S.T.; writing—review and editing, S.T., S.M., and R.B.; funding acquisition, R.B. and S.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Ministero della salute Ricerca Corrente (2022–2024, to R.B. and S.M.).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Xie, Y.-H.; Chen, Y.-X.; Fang, J.-Y. Comprehensive Review of Targeted Therapy for Colorectal Cancer. Signal Transduct. Target. Ther. 2020, 5, 22. [Google Scholar] [CrossRef]
  2. Nistal, E.; Fernández-Fernández, N.; Vivas, S.; Olcoz, J.L. Factors Determining Colorectal Cancer: The Role of the Intestinal Microbiota. Front. Oncol. 2015, 5, 220. [Google Scholar] [CrossRef] [PubMed]
  3. Durko, L.; Malecka-Panas, E. Lifestyle Modifications and Colorectal Cancer. Curr. Colorectal Cancer Rep. 2014, 10, 45–54. [Google Scholar] [CrossRef] [PubMed]
  4. Murphy, N.; Moreno, V.; Hughes, D.J.; Vodicka, L.; Vodicka, P.; Aglago, E.K.; Gunter, M.J.; Jenab, M. Lifestyle and Dietary Environmental Factors in Colorectal Cancer Susceptibility. Mol. Aspects Med. 2019, 69, 2–9. [Google Scholar] [CrossRef]
  5. Pietrzyk, Ł. Food Properties and Dietary Habits in Colorectal Cancer Prevention and Development. Int. J. Food Prop. 2017, 20, 2323–2343. [Google Scholar] [CrossRef]
  6. Vernocchi, P.; Del Chierico, F.; Putignani, L. Gut Microbiota Metabolism and Interaction with Food Components. Int. J. Mol. Sci. 2020, 21, 3688. [Google Scholar] [CrossRef] [PubMed]
  7. Moszak, M.; Szulińska, M.; Bogdański, P. You Are What You Eat-The Relationship between Diet, Microbiota, and Metabolic Disorders-A Review. Nutrients 2020, 12, 1096. [Google Scholar] [CrossRef]
  8. Kim, J.; Lee, H.K. Potential Role of the Gut Microbiome In Colorectal Cancer Progression. Front. Immunol. 2022, 12, 807648. [Google Scholar] [CrossRef]
  9. Loke, Y.L.; Chew, M.T.; Ngeow, Y.F.; Lim, W.W.D.; Peh, S.C. Colon Carcinogenesis: The Interplay Between Diet and Gut Microbiota. Front. Cell. Infect. Microbiol. 2020, 10, 603086. [Google Scholar] [CrossRef] [PubMed]
  10. Zheng, D.; Liwinski, T.; Elinav, E. Interaction between Microbiota and Immunity in Health and Disease. Cell Res. 2020, 30, 492–506. [Google Scholar] [CrossRef]
  11. Belkaid, Y.; Hand, T.W. Role of the Microbiota in Immunity and Inflammation. Cell 2014, 157, 121–141. [Google Scholar] [CrossRef]
  12. Ahn, J.; Sinha, R.; Pei, Z.; Dominianni, C.; Wu, J.; Shi, J.; Goedert, J.J.; Hayes, R.B.; Yang, L. Human Gut Microbiome and Risk for Colorectal Cancer. JNCI J. Natl. Cancer Inst. 2013, 105, 1907–1911. [Google Scholar] [CrossRef] [PubMed]
  13. Hannigan, G.D.; Duhaime, M.B.; Ruffin, M.T.; Koumpouras, C.C.; Schloss, P.D. Diagnostic Potential and Interactive Dynamics of the Colorectal Cancer Virome. mBio 2018, 9, e02248-18. [Google Scholar] [CrossRef] [PubMed]
  14. Gao, R.; Kong, C.; Li, H.; Huang, L.; Qu, X.; Qin, N.; Qin, H. Dysbiosis Signature of Mycobiota in Colon Polyp and Colorectal Cancer. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 2457–2468. [Google Scholar] [CrossRef] [PubMed]
  15. Kolodny, O.; Schulenburg, H. Microbiome-Mediated Plasticity Directs Host Evolution along Several Distinct Time Scales. Philos. Trans. R. Soc. B Biol. Sci. 2020, 375, 20190589. [Google Scholar] [CrossRef]
  16. Yang, Y.; Gharaibeh, R.; Jobin, C. Abstract IA07: The Plasticity of the Intestinal Microbiota in Colorectal Cancer. Cancer Res. 2020, 80, IA07. [Google Scholar] [CrossRef]
  17. Conlon, M.A.; Bird, A.R. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. Nutrients 2015, 7, 17–44. [Google Scholar] [CrossRef] [PubMed]
  18. Campaniello, D.; Corbo, M.R.; Sinigaglia, M.; Speranza, B.; Racioppo, A.; Altieri, C.; Bevilacqua, A. How Diet and Physical Activity Modulate Gut Microbiota: Evidence, and Perspectives. Nutrients 2022, 14, 2456. [Google Scholar] [CrossRef]
  19. Dalton, A.; Mermier, C.; Zuhl, M. Exercise Influence on the Microbiome-Gut-Brain Axis. Gut Microbes 2019, 10, 555–568. [Google Scholar] [CrossRef]
  20. Ningthoujam, D.S.; Singh, N.; Mukherjee, S. Possible Roles of Cyclic Meditation in Regulation of the Gut-Brain Axis. Front. Psychol. 2021, 12, 768031. [Google Scholar] [CrossRef]
  21. Sánchez-Alcoholado, L.; Ramos-Molina, B.; Otero, A.; Laborda-Illanes, A.; Ordóñez, R.; Medina, J.A.; Gómez-Millán, J.; Queipo-Ortuño, M.I. The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response. Cancers 2020, 12, 1406. [Google Scholar] [CrossRef] [PubMed]
  22. Hanus, M.; Parada-Venegas, D.; Landskron, G.; Wielandt, A.M.; Hurtado, C.; Alvarez, K.; Hermoso, M.A.; López-Köstner, F.; De la Fuente, M. Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment. Front. Immunol. 2021, 12, 612826. [Google Scholar] [CrossRef]
  23. Lu, S.S.M.; Mohammed, Z.; Häggström, C.; Myte, R.; Lindquist, E.; Gylfe, Å.; Van Guelpen, B.; Harlid, S. Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study. JNCI J. Natl. Cancer Inst. 2022, 114, 38–46. [Google Scholar] [CrossRef] [PubMed]
  24. Martin, O.C.B.; Lin, C.; Naud, N.; Tache, S.; Raymond-Letron, I.; Corpet, D.E.; Pierre, F.H. Antibiotic Suppression of Intestinal Microbiota Reduces Heme-Induced Lipoperoxidation Associated with Colon Carcinogenesis in Rats. Nutr. Cancer 2015, 67, 119–125. [Google Scholar] [CrossRef] [PubMed]
  25. Dik, V.K.; van Oijen, M.G.H.; Smeets, H.M.; Siersema, P.D. Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Case–Control Study. Dig. Dis. Sci. 2016, 61, 255–264. [Google Scholar] [CrossRef]
  26. Boursi, B.; Haynes, K.; Mamtani, R.; Yang, Y.-X. Impact of Antibiotic Exposure on the Risk of Colorectal Cancer. Pharmacoepidemiol. Drug Saf. 2015, 24, 534–542. [Google Scholar] [CrossRef]
  27. Yuan, L.; Zhang, S.; Li, H.; Yang, F.; Mushtaq, N.; Ullah, S.; Shi, Y.; An, C.; Xu, J. The Influence of Gut Microbiota Dysbiosis to the Efficacy of 5-Fluorouracil Treatment on Colorectal Cancer. Biomed. Pharmacother. 2018, 108, 184–193. [Google Scholar] [CrossRef]
  28. Makki, K.; Deehan, E.C.; Walter, J.; Bäckhed, F. The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. Cell Host Microbe 2018, 23, 705–715. [Google Scholar] [CrossRef]
  29. Dahm, C.C.; Keogh, R.H.; Spencer, E.A.; Greenwood, D.C.; Key, T.J.; Fentiman, I.S.; Shipley, M.J.; Brunner, E.J.; Cade, J.E.; Burley, V.J.; et al. Dietary Fiber and Colorectal Cancer Risk: A Nested Case-Control Study Using Food Diaries. J. Natl. Cancer Inst. 2010, 102, 614–626. [Google Scholar] [CrossRef]
  30. Bingham, S.A.; Day, N.E.; Luben, R.; Ferrari, P.; Slimani, N.; Norat, T.; Clavel-Chapelon, F.; Kesse, E.; Nieters, A.; Boeing, H.; et al. Dietary Fibre in Food and Protection against Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An Observational Study. Lancet 2003, 361, 1496–1501. [Google Scholar] [CrossRef]
  31. Moen, B.; Henjum, K.; Måge, I.; Knutsen, S.H.; Rud, I.; Hetland, R.B.; Paulsen, J.E. Effect of Dietary Fibers on Cecal Microbiota and Intestinal Tumorigenesis in Azoxymethane Treated A/J Min/+ Mice. PLoS ONE 2016, 11, e0155402. [Google Scholar] [CrossRef]
  32. Song, M.; Wu, K.; Meyerhardt, J.A.; Ogino, S.; Wang, M.; Fuchs, C.S.; Giovannucci, E.L.; Chan, A.T. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol. 2018, 4, 71–79. [Google Scholar] [CrossRef] [PubMed]
  33. Mehta, R.S.; Nishihara, R.; Cao, Y.; Song, M.; Mima, K.; Qian, Z.R.; Nowak, J.A.; Kosumi, K.; Hamada, T.; Masugi, Y.; et al. Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium Nucleatum in Tumor Tissue. JAMA Oncol. 2017, 3, 921–927. [Google Scholar] [CrossRef]
  34. Sun, C.-H.; Li, B.-B.; Wang, B.; Zhao, J.; Zhang, X.-Y.; Li, T.-T.; Li, W.-B.; Tang, D.; Qiu, M.-J.; Wang, X.-C.; et al. The Role of Fusobacterium Nucleatum in Colorectal Cancer: From Carcinogenesis to Clinical Management. Chronic Dis. Transl. Med. 2019, 5, 178–187. [Google Scholar] [CrossRef]
  35. Biswas, V.; Praveen, A.; Marisetti, A.L.; Sharma, A.; Kumar, V.; Sahu, S.K.; Tewari, D. A Mechanistic Overview on Impact of Dietary Fibres on Gut Microbiota and Its Association with Colon Cancer. Dietetics 2022, 1, 17. [Google Scholar] [CrossRef]
  36. O’Keefe, S.J.D.; Li, J.V.; Lahti, L.; Ou, J.; Carbonero, F.; Mohammed, K.; Posma, J.M.; Kinross, J.; Wahl, E.; Ruder, E.; et al. Fat, Fibre and Cancer Risk in African Americans and Rural Africans. Nat. Commun. 2015, 6, 6342. [Google Scholar] [CrossRef]
  37. Aglago, E.K.; Huybrechts, I.; Murphy, N.; Casagrande, C.; Nicolas, G.; Pischon, T.; Fedirko, V.; Severi, G.; Boutron-Ruault, M.-C.; Fournier, A.; et al. Consumption of Fish and Long-Chain n-3 Polyunsaturated Fatty Acids Is Associated With Reduced Risk of Colorectal Cancer in a Large European Cohort. Clin. Gastroenterol. Hepatol. 2020, 18, 654–666.e6. [Google Scholar] [CrossRef] [PubMed]
  38. Hong, M.Y.; Turner, N.D.; Murphy, M.E.; Carroll, R.J.; Chapkin, R.S.; Lupton, J.R. In Vivo Regulation of Colonic Cell Proliferation, Differentiation, Apoptosis, and P27Kip1 by Dietary Fish Oil and Butyrate in Rats. Cancer Prev. Res. (Phila. Pa.) 2015, 8, 1076–1083. [Google Scholar] [CrossRef]
  39. Song, M.; Nishihara, R.; Wu, K.; Qian, Z.R.; Kim, S.A.; Sukawa, Y.; Mima, K.; Inamura, K.; Masuda, A.; Yang, J.; et al. Marine ω-3 Polyunsaturated Fatty Acids and Risk of Colorectal Cancer According to Microsatellite Instability. J. Natl. Cancer Inst. 2015, 107, djv007. [Google Scholar] [CrossRef]
  40. Yang, K.; Li, H.; Dong, J.; Dong, Y.; Wang, C.-Z. Expression Profile of Polyunsaturated Fatty Acids in Colorectal Cancer. World J. Gastroenterol. 2015, 21, 2405–2412. [Google Scholar] [CrossRef]
  41. Tripathy, A.; Dash, J.; Kancharla, S.; Kolli, P.; Mahajan, D.; Senapati, S.; Jena, M.K. Probiotics: A Promising Candidate for Management of Colorectal Cancer. Cancers 2021, 13, 3178. [Google Scholar] [CrossRef] [PubMed]
  42. Drago, L. Probiotics and Colon Cancer. Microorganisms 2019, 7, 66. [Google Scholar] [CrossRef]
  43. Chang, C.-W.; Liu, C.-Y.; Lee, H.-C.; Huang, Y.-H.; Li, L.-H.; Chiau, J.-S.C.; Wang, T.-E.; Chu, C.-H.; Shih, S.-C.; Tsai, T.-H.; et al. Lactobacillus Casei Variety Rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model. Front. Microbiol. 2018, 9, 983. [Google Scholar] [CrossRef]
  44. Briguglio, G.; Costa, C.; Pollicino, M.; Giambò, F.; Catania, S.; Fenga, C. Polyphenols in Cancer Prevention: New Insights (Review). Int. J. Funct. Nutr. 2020, 1, 1. [Google Scholar] [CrossRef]
  45. Xavier, C.P.R.; Lima, C.F.; Rohde, M.; Pereira-Wilson, C. Quercetin Enhances 5-Fluorouracil-Induced Apoptosis in MSI Colorectal Cancer Cells through P53 Modulation. Cancer Chemother. Pharmacol. 2011, 68, 1449–1457. [Google Scholar] [CrossRef]
  46. Shakibaei, M.; Buhrmann, C.; Kraehe, P.; Shayan, P.; Lueders, C.; Goel, A. Curcumin Chemosensitizes 5-Fluorouracil Resistant MMR-Deficient Human Colon Cancer Cells in High Density Cultures. PLoS ONE 2014, 9, e85397. [Google Scholar] [CrossRef] [PubMed]
  47. Buhrmann, C.; Shayan, P.; Kraehe, P.; Popper, B.; Goel, A.; Shakibaei, M. Resveratrol Induces Chemosensitization to 5-Fluorouracil through up-Regulation of Intercellular Junctions, Epithelial-to-Mesenchymal Transition and Apoptosis in Colorectal Cancer. Biochem. Pharmacol. 2015, 98, 51–68. [Google Scholar] [CrossRef] [PubMed]
  48. Himbert, C.; Stephens, W.Z.; Gigic, B.; Hardikar, S.; Holowatyj, A.N.; Lin, T.; Ose, J.; Swanson, E.; Ashworth, A.; Warby, C.A.; et al. Differences in the Gut Microbiome by Physical Activity and BMI among Colorectal Cancer Patients. Am. J. Cancer Res. 2022, 12, 4789–4801. [Google Scholar]
  49. Wang, Z.; Liu, S.; Xu, X.; Xiao, Y.; Yang, M.; Zhao, X.; Jin, C.; Hu, F.; Yang, S.; Tang, B.; et al. Gut Microbiota Associated With Effectiveness And Responsiveness to Mindfulness-Based Cognitive Therapy in Improving Trait Anxiety. Front. Cell. Infect. Microbiol. 2022, 12, 719829. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tardito, S.; Matis, S.; Benelli, R. The Pleiotropic Effects of Gut Microbiota in Colorectal Cancer Progression: How to Turn Foes into Friends. Cancers 2023, 15, 916. https://doi.org/10.3390/cancers15030916

AMA Style

Tardito S, Matis S, Benelli R. The Pleiotropic Effects of Gut Microbiota in Colorectal Cancer Progression: How to Turn Foes into Friends. Cancers. 2023; 15(3):916. https://doi.org/10.3390/cancers15030916

Chicago/Turabian Style

Tardito, Samuele, Serena Matis, and Roberto Benelli. 2023. "The Pleiotropic Effects of Gut Microbiota in Colorectal Cancer Progression: How to Turn Foes into Friends" Cancers 15, no. 3: 916. https://doi.org/10.3390/cancers15030916

APA Style

Tardito, S., Matis, S., & Benelli, R. (2023). The Pleiotropic Effects of Gut Microbiota in Colorectal Cancer Progression: How to Turn Foes into Friends. Cancers, 15(3), 916. https://doi.org/10.3390/cancers15030916

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop